TORONTO, Oct. 26, 2018 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF) (FSE: 31R) (“Revive” or the “Company”), a specialty cannabis company focused on the research, development and commercialization of novel cannabinoid-based products, today announced its results for the fiscal year ended June 30, 2018. The Audited Financial Statements and Management’s Discussion and Analysis for the year ended June 30, 2018, may be viewed on SEDAR at www.sedar.com.
Operational Activities Achieved in 2018
- Entered into exclusive licence agreement with South Carolina Research Foundation for cannabinoid-based therapeutics in the treatment of liver diseases, specifically cannabidiol in the treatment of autoimmune disease;
- Entered into exclusive licence agreement with Wisconsin Alumni Research Foundation for cannabinoid delivery technology;
- Entered into medical cannabis RD supply and collaboration agreements with WeedMD Rx Inc.;
- Entered into collaboration agreement with Chemi Pharmaceutical Inc., a Health Canada licensed dealer for medical